Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP) (ESCDP)
Diabetes Mellitus, Type 2, Cognitive Functions Confusion
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes mellitus, Cognitive Functions, Sodium glucose transporter
Eligibility Criteria
Inclusion Criteria:
- Early onset type 2 diabetes within 3 months 7%<HbA1c<10%
Exclusion Criteria:
- Type 2 diabetes with acute diabetic complications. Type1 diabetes. Other diseases affecting cognitive function (congenital dementia, brain trauma, severe heartdysfunction,severekidneydysfunction,severelungdysfunction, epilepsy, severe hypoglycemic coma, cerebrovascular disease, ischemic heart disease, etc.); Alcohol abuse,mental illness and psychoactive substance abuse History of thyroid disease Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs.
Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs.
History of depression, schizophrenia or dementia. History of cardio-cerebral vascular events, such as congestive heart failure, myocardial infarction or stroke within 3 months.
History of parkinson's diseases, head injury,toxicencephacopathy,epilepsy. Hypohepatia (AST or AST is twice higher than the upper limit) or history of hepatitis or cirrhosis, hepatic encephalopathy.
Renal insufficiency (serum creatinine 1.5 times higher than the upper limit) or history of dialysis and nephritic syndrome.
Acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine addiction.
Fertile woman without contraceptives. Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs.
Allergic to or have contraindication to the intervention drugs.
Sites / Locations
- The third hospital affiliated to the Army Medical UniversityRecruiting
- Zhiming ZhuRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Dapagliflozin
Metformin
12 weeks of Dapagliflozin(10mg/day) treatment, randomly
12 weeks of Metformin (1500-2000mg/day) treatment, randomly